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   The new coronavirus pandemic, called COVID-19 (CoV-2), originated in China around November 
2019 and has gradually spread all over the world, upsetting our lives. To date (April 4, 2020) more than 
1 million people in the world have tested positive (and 10 times as many are likely to be infected) and 
around 60,000 have died (this figure also seems highly underestimated), Italy ranks first in this list, and 
the number of new infections is still increasing steadily. Mortality, which in Italy has exceeded 12% of 
the infected, seems to be conditioned by the presence of comorbidities such as high blood pressure, 
diabetes, chronic bronchitis.1 Thus, these conditions lead to frailty of the affected patients.2,3 
Inflammatory bowel diseases (IBDs) are not mentioned among these conditions. 
   IBDs are immune-mediated diseases in which a dysregulated reaction of the immune system towards 
the intestinal microbiome induces a chronic inflammation that causes progressive damage. Despite an 
inflammatory core centred on the bowel,4 IBDs could be associated to several extra-intestinal 
manifestations.5 These diseases particularly affect young people, requiring a chronic management as 
well as the use of immunosuppressant and biological drugs6 raising obvious safety issues. 
   Furthermore, the digestive tract does not appear to be immune from COVID-19 involvement. The 
antagonist angiotensin-converting enzyme 2 (ACE2), which main function is to negatively regulate the 
renin-angiotensin system, is the COVID-19 gate to our cells.7 Lung, kidney, and gut cells all express 
ACE2 receptors. Not surprisingly, gastrointestinal symptoms are part (albeit with limited clinical 
importance) of the expression of the infection from severe acute respiratory syndrome (SARS)-CoV-2.8   
   To date, April 4, 2020, more than 275 cases of IBD patients infected by COVID-19 are reported 
worldwide.9 Obviously, we do not yet have data to know whether IBD patients are at an increased risk 
of COVID-19 infection due to the disease itself or because of the drugs they are treated with.10 In this 
perspective, a study published in 2009 could be informative. The authors used two mouse models 
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younger animals responded with a “cytokine storm” including major pro-inflammatory cytokines and 
interferon (IFN), with the older succumbing to this mixture more than the younger.11 The key message 
is that disease behavior does mostly depend on host immunity, with full blown deadly reactions most 
probable at advanced age. 
   Coherently with this premise, the preference of IBD for younger age cohorts should reassure us on 
their outcomes in COVID infection; the role of medications in this context is mixed, however. The 
example of the possible beneficial role of tocilizumab (anti-interleukin-6 drug) in limiting the cytokine  
storm is an important example.12 In this regard, how should we advise our IBD patients? 
   Patients with IBD should not be routinely considered to have an altered immunocompetence per se, 
despite evidence of impaired innate mucosal immunity.13 If we can safely state that our patients can 
continue mesalazine therapy without concern, we know that the immunomodulators commonly used in 
IBD (corticosteroids, thiopurines, methotrexate, calcineurin inhibitors, anti-Tumor Necrosis Factor 
agents and other biologics) are associated with an increased risk of infections, especially if they are 
used in combination or in older patients. For corticosteroids, a total daily dose equivalent to ≥ 20 mg of 
prednisolone for ≥ 2 weeks is associated with an increased risk of infections.14  
   While the incidence of influenza does not appear greater in patients affected by IBD receiving 
immunomodulators, immunosuppression is generally considered to enhance the risk of 
severe/complicated influenza infection and immunosuppressed patients with a laboratory diagnosis of 
influenza should receive timely treatment early in the course of illness.14 Withdrawal of immune 
suppression is advisable in the case of ascertained COVID-19 infection; yet, preemptive withdrawal is 
not wise, if considering a possible severe flare.15  
   Chronic IBD patients subjected to long-term treatment on one hand, and physical distancing 
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This could be the ideal test opportunity for telemedicine. The use of telemonitoring and teleconsulting 
seems to be safe and feasible with excellent patient acceptance.17 These can be implemented to enhance 
monitoring of disease activity and toxicity of therapy and promote empowerment and improvement of 
patient quality of life. However, this cannot be done by the individual clinician  rather the Health 
Authority must fully be involved. 
   In conclusion, COVID superinfection will make a double endeavor on all physicians and IBD 
caregivers, reinforcing rules already applied for compromised hosts exposed to infection: prevent 
contact with potential sources, avoid starting therapeutic strategies with 2 immunomodulatory drugs, 
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